Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Grote globale verschillen in implementatie van hypofractionering bij radiotherapie
nov 2018 | Borstkanker, Radiotherapie, Uro-oncologie